Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A clinical review of CJC-1295 modified GRF and its potential impact on cognitive function, including GH/IGF-1 signaling pathways, trial data, dosing considerations, and what patients should realistically expect.
Read clinical reviewA clinical deep-dive into how CJC-1295 (modified GRF 1-29) influences growth hormone pulsatility, lipolysis, resting metabolic rate, and body composition, with primary-literature citations and dosing context for telehealth prescribers.
Read clinical reviewA clinician-level review of how CJC-1295 modified GRF affects appetite, hunger hormones, and food cravings, with primary-literature citations and practical dosing context.
Read clinical reviewA physician-level review of CJC-1295 modified GRF use in patients with autoimmune conditions, covering IGF-1 immunomodulation, disease-specific risks, monitoring protocols, and current evidence gaps.
Read clinical reviewA clinician-level review of how CJC-1295 modified GRF affects bone mineral density, osteoblast activity, and fracture risk, with primary-literature citations and dosing context.
Read clinical reviewA physician-level review of CJC-1295 (modified GRF 1-29) and cancer risk, covering IGF-1 biology, preclinical data, the Teichman trial, and how clinicians should weigh these signals before prescribing.
Read clinical reviewA clinician-level review of CJC-1295 (modified GRF) cardiovascular effects, covering cardiac output, blood pressure, lipid remodeling, IGF-1 signaling, and long-term risk framing based on primary literature.
Read clinical reviewA physician-reviewed comparison of compounded CJC-1295 (modified GRF 1-29) versus branded growth hormone secretagogue formulations, covering pharmacokinetics, dosing, regulatory status, purity data, and clinical evidence from Teichman et al. And related trials.
Read clinical reviewA rigorous GRADE-level review of CJC-1295 (modified GRF) clinical evidence, covering pharmacology, trial data from Teichman et al. 2006, and what the research does and does not support for GH secretagogue therapy.
Read clinical reviewA physician-reviewed deep dive into how CJC-1295 (modified GRF) affects hair growth, skin thickness, collagen synthesis, and sebum production, with primary-literature citations and dosing context.
Read clinical reviewA physician-level review of how CJC-1295 (modified GRF) affects liver enzymes, IGF-1 hepatic signaling, and clinical safety markers, with primary-literature citations.
Read clinical reviewA clinician-level review of how CJC-1295 (modified GRF) affects mood, cognition, sleep quality, and mental health outcomes, with primary-literature citations and dosing context.
Read clinical reviewA physician-reviewed analysis of CJC-1295 microdosing protocols, covering the pharmacokinetics, available clinical data, dosing frameworks used in 503A compounding practice, and what board-certified endocrinologists say about evidence gaps.
Read clinical reviewA physician-reviewed breakdown of CJC-1295 modified GRF for muscle preservation, covering mechanism, dosing protocols, clinical evidence, and how to combine it safely with resistance training and nutrition.
Read clinical reviewMD/PharmD-level guide to diagnosing and correcting CJC-1295 plateaus and non-response: receptor downregulation, dosing errors, injection technique, IGF-1 monitoring, and evidence-based fixes.
Read clinical reviewA physician-reviewed guide to CJC-1295 (modified GRF) use after bariatric surgery, covering pharmacology, GH/IGF-1 dynamics, dosing considerations, safety, and the evidence base including Teichman et al. 2006.
Read clinical reviewEvidence-based guidance on how long to hold CJC-1295 (modified GRF) before surgery, including GH physiology, anesthesia interactions, and restart timing from HealthRX physicians.
Read clinical reviewDoes stopping CJC-1295 cause rebound effects? A physician-reviewed guide covering GH axis suppression, IGF-1 normalization timelines, and what the clinical literature says about discontinuation.
Read clinical reviewA clinical review of CJC-1295 modified GRF and its effects on renal function, covering GH/IGF-1 physiology, animal data, human pharmacokinetics, known risks, and prescribing considerations for patients with kidney disease.
Read clinical reviewEvidence-based protocol for restarting CJC-1295 modified GRF after acute illness. Covers timing, dose titration, IGF-1 monitoring, and contraindications reviewed by the HealthRX medical team.
Read clinical reviewA physician-reviewed guide to CJC-1295 (modified GRF) seasonal use considerations, including dosing adjustments, GH pulsatility, IGF-1 monitoring, and timing protocols across winter and summer cycles.
Read clinical reviewA clinical deep-dive into how CJC-1295 (modified GRF) affects libido, erectile function, and hormonal pathways related to sexual health, with primary-literature citations and dosing context.
Read clinical reviewA physician-reviewed, primary-literature analysis of how CJC-1295 (modified GRF) affects slow-wave sleep, GH pulse timing, and overnight IGF-1 secretion, with dosing context and clinical considerations.
Read clinical reviewBoard-reviewed protocols for adjusting CJC-1295 (modified GRF) dosing schedules across time zones, including jet-lag pharmacology, storage during travel, and dose-timing decision frameworks.
Read clinical reviewA physician-reviewed, week-by-week guide to CJC-1295 (modified GRF 1-29) covering sleep, body composition, IGF-1 kinetics, and dosing protocols across the first four weeks.
Read clinical review